Not independent
Tenure on this board
2.2 yrs
Also a director at
Ibio Inc (IBIO)Contineum Therapeutics Inc (CTNM)
3 nominees · 2 ballot items.
Elect three Class II directors and ratify Ernst & Young LLP as independent auditors for the 2026 fiscal year.
Elect three Class II directors (Evert Schimmelpennink, Jeff George and Shelley Thunen) to hold office until the 2029 annual meeting of stockholders.
Ratify the appointment of Ernst & Young LLP as LENZ Therapeutics, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 13.3% | 4,178,823 | $38M |
| 2 | Alpha Wave Global, LP | 11.5% | 3,612,211 | $33M |
| 3 | Versant Venture Management, LLC | 8.5% | 2,656,888 | $24M |
| 4 | FMR LLC | 6.2% | 1,948,464 | $18M |
| 5 | FMR LLC | 5.3% | 1,649,278 | $15M |
| 6 | Squarepoint Ops LLC | 4.8% | 1,506,499 | $14M |
| 7 | Aberdeen Group plc | 3.7% | 1,156,161 | $11M |
| 8 | FRANKLIN RESOURCES INC | 3.5% | 1,092,259 | $10M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 1,041,188 | $10M |
| 10 | 72 Investment Holdings, LLC | 3.2% | 1,017,751 | $9M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.